Table 1.
Characteristics of randomised population. Data are mean (s.d.) unless otherwise indicated.
| IDegAsp | AF | BIAsp 30 | |
|---|---|---|---|
| na | 61 | 59 | 62 |
| Sex: male/female (%) | 48/52 | 49/51 | 63/37 |
| Race: W/B (n) | 60/1 | 58/1 | 61/1 |
| Age (years) | 58.7 (8.5) | 60.5 (8.9) | 59.7 (8.0) |
| Weight (kg) | 87.8 (16.3) | 84.9 (14.3) | 91.8 (13.5) |
| Height (m) | |||
| BMI (kg/m2) | 31.5 (3.6) | 30.8 (3.6) | 31.9 (3.5) |
| Duration of diabetes (years) | 9.0 (6.1) | 10.7 (6.4) | 8.6 (6.3) |
| HbA1c (%) | 8.5 (1.2) | 8.5 (0.9) | 8.6 (1.0) |
| FPG (mmol/l) | 11.4 (2.7) | 11.8 (2.9) | 11.7 (3.1) |
| Pre-study OAD treatment (n (%)) | |||
| Met and/or α-gluc | 14 (23) | 13 (22) | 14 (23) |
| SU and/or α-gluc | 2 (3) | 2 (3) | 2 (3) |
| Met and SU | 45 (74) | 45 (74) | 46 (74) |
W, white; B, black or African American; Met, metformin; SU, sulphonylurea; α-gluc, α-glucosidase inhibitor.
a
Full analysis set (all randomised subjects).